HDAC3 and breast carcinoma: To confirm that HDAC6 and HDAC3 could regulate survivin acetylation in breast cancer cells, MCF7 cells were treated with BML281 and RGFP966, which are pharmacological inhibitors of HDAC6 and HDAC3, respectively, and the expression of acetylated survivin was again determined by Western blotting.